HomeInsights52 Week Low Stocks

Zydus Lifesciences Ltd 52 Week Low

Zydus Lifesciences Ltd 52 Week Low

stocks purchased

₹ 6.3 Cr

Volume Transacted

(Nov 7, 2024)

stocks purchased

64.7 K

Stocks Traded

(Nov 7, 2024)

Last Updated on: Nov 08, 2024

Image

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE

YEARLOW

₹ 598.05

Last updated on: Nov 07, 2024

Key Highlights

  • The 52 Week Low of Zydus Lifesciences Ltd is ₹ 598.05 as of 07 Nov 24.

Company Fundamentals for Zydus Lifesciences Ltd

No data available

Market Price Over Time

1M

1Y

3Y

5Y

Monitoring Zydus Lifesciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
07 Nov 2024972.6
06 Nov 2024995
05 Nov 2024989.3
04 Nov 20241004.3
01 Nov 20241004
31 Oct 20241001.85
30 Oct 2024985.55
29 Oct 20241002.3
28 Oct 20241006.65
25 Oct 2024990.2

Asset Value vs Market Value of Zydus Lifesciences Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Historical Revenue of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical Net Profit of Zydus Lifesciences Ltd

No data available

* All values are in crore

Zydus Lifesciences Ltd News Hub

News

Zydus Lifesciences to table results

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 Nove...

Read more

31 Oct 202411:58

News

Zydus Life rises on in-principle approval from WHO for typhoid vaccine

ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. It is indigenously...

Read more

23 Oct 202414:50

News

Zydus receives USFDA approval for Fludrocortisone Acetate Tablets

Zydus Lifesciences has received final approval from the United States Food and Drug Admini...

Read more

18 Oct 202409:29

News

Zydus Life gets final approval from USFDA for Fludrocortisone Acetate tab

Fludrocortisone Acetate tablets are indicated as partial replacement therapy for primary a...

Read more

18 Oct 202412:47

News

Zydus partners with ICMR to initiate Phase 2 clinical trials of Desidustat oral tablet for treating sickle cell disease

Zydus Lifesciences has formalized the Memorandum of Agreement (MoA) with Indian Council of...

Read more

15 Oct 202410:08

News

Zydus Life gets final approval from USFDA for Paliperidone drug

Paliperidone extended-release tablets are indicated for the acute and maintenance treatmen...

Read more

10 Oct 202414:51

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for 52 Week Low of Zydus Lifesciences Ltd

Why is it important to track the 52-week low of Zydus Lifesciences Ltd stocks?

Investors should monitor the 52-week low of Zydus Lifesciences Ltd stocks regularly to stay informed about significant price changes and assess the stock's performance over time. Frequent monitoring will help traders identify trends and make timely decisions.

What factors can lead to Zydus Lifesciences Ltd stocks hitting a 52-week low?

Factors leading to Zydus Lifesciences Ltd stocks hitting a 52-week low may include poor fiscal results, negative industry trends, macroeconomic issues, or management changes. Other factors such as market volatility and broader economic downturns can also contribute to a 52-week low.

Should investors buy Zydus Lifesciences Ltd stocks when they hit a 52-week low?

Buying Zydus Lifesciences Ltd stocks at a 52-week low can offer a potential bargain, however, it is crucial to evaluate the reasons behind the stock price drop and ensure there is no underlying fundamental issue. Investors should consider the company's long-term prospects before making a buying decision.

How often should investors monitor the 52-week low of Zydus Lifesciences Ltd stocks?

Investors should monitor the 52-week low of Zydus Lifesciences Ltd stocks regularly to stay informed about significant price changes and assess the stock's performance over time, which will help them identify trends and make timely decisions.

How can an investor assess the risk of buying Zydus Lifesciences Ltd stock at their 52-week low?

An investor can analyze the reasons for the Zydus Lifesciences Ltd stock price drop, evaluate the company’s fundamentals, and consider market conditions. Investors should also review the stock’s historical performance and any potential recovery indicators.

Should investors consider the overall market trend when evaluating Zydus Lifesciences Ltd stocks at their 52-week low?

Certainly, considering the overall market trend when evaluating Zydus Lifesciences Ltd stocks at their 52-week low is significant as it provides context for the stock’s performance and potential future movements. A declining market trend may influence Zydus Lifesciences Ltd stock performance, impacting the timing and potential of the investment.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*